Skip to main content
Clinical Trials/NCT06694415
NCT06694415RecruitingNot Applicable

Determining Paediatric Usual Values for Hormones Dosages by Mass Spectrometry

Assistance Publique - Hôpitaux de Paris1 site in 1 country1,500 target enrollmentStarted: January 2, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
1,500
Locations
1
Primary Endpoint
to determine paediatric usual values for hormones dosages by mass spectrometry

Study Overview

Brief Summary

Liquid chromatography coupled with mass spectrometry (LC-MS/MS) is now the method of choice for steroid hormone analysis, as it enables analyses to be carried out on small-volume samples on a wider range of hormones, with improved specificity compared with immunoassays. Hormone assays currently face a twofold problem: on the one hand, immunoassays are highly dependent on the synthesis of antibody kits manufactured by companies with immunotechnology expertise; on the other hand, these immunoassays may require the use of radioactive products for quantification, generating considerable risks for both staff and environment. There are international recommendations from expert societies (World Anti-Doping Agency, Endocrine society) to develop new, more reliable assay methods, such as LC-MS/MS, and to phase out immuno- and radioassay techniques.

However, changing measurement methods requires the development of reference values to maintain and optimize the management of patients.

The aim of this project is therefore to establish usual values in a paediatric population, through collaboration between the clinical departments of the APHP and the METOMICS laboratory, which has mastered the technology.

Detailed Description

This is a prospective, multicentric, non-randomized. The study will be uncontrolled, as it will use subjects considered "healthy" to establish reference values.

Recruitment is planned to take place in hospital consultations at recruiting centers belonging to the AP-HP.

During the blood sample prescribed as part of the follow-up consultation, an additional blood tube will be collected after information, consent and inclusion.

The following acts and procedures will be added as part of the research:

  • additional tube, respecting the total volume taken according to weight (maximum volume of 2.7mL);
  • Routine circuit for sending and receiving the tube to ensure the relevance of standards established in real life.
  • A biological collection will be set up. Pseudonymized data will be collected on a secure REDCap database. The source data will be: Recruiting center; Age; Gender; Pubertal stage if available; Results of blood tests carried out by mass spectrometry as part of this research.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
— to 20 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Male or female patient ≤ 20 years old
  • undergoing a blood sample as part of their pathology routine follow-up

Exclusion Criteria

  • Any identified or suspected endocrine pathology
  • Any acute infectious or inflammatory disorder

Outcomes

Primary Outcomes

to determine paediatric usual values for hormones dosages by mass spectrometry

Time Frame: 1 week

internal quality control (IQC) suitability/match between the one provided by the manufacturer or developed in-house, and inter-laboratory comparisons (EQA/EIL)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials